Stewart D, Blendis L M, Williams R
J Clin Pathol. 1972 May;25(5):410-4. doi: 10.1136/jcp.25.5.410.
The plasma prekallikrein-bradykininogen system was studied in 45 patients with chronic liver disease since its activation with increased liberation of kinin into the plasma could account for some of the clinical manifestations of cirrhosis, namely, vasodilatation, hypotension, and increased capillary permeability.A significant reduction in plasma bradykininogen was found in the cirrhotic patients as compared with control groups of normal subjects and hospital inpatients. The mean plasma prekallikrein was not significantly different and only five patients with liver disease had reduced levels. The most likely explanation for the low plasma bradykininogen was impairment of synthesis by the cirrhotic liver, the usually normal prekallikrein levels making the other possibility of increased activation of bradykininogen to bradykinin in the plasma less likely.
对45例慢性肝病患者的血浆前激肽释放酶-缓激肽原系统进行了研究，因为该系统的激活以及激肽向血浆中释放的增加可能是肝硬化某些临床表现的原因，即血管扩张、低血压和毛细血管通透性增加。与正常受试者对照组和医院住院患者相比，肝硬化患者血浆缓激肽原显著降低。血浆前激肽释放酶的平均值无显著差异，只有5例肝病患者水平降低。血浆缓激肽原水平低的最可能解释是肝硬化肝脏合成功能受损，通常正常的前激肽释放酶水平使得血浆中缓激肽原被激活为缓激肽增加的可能性较小。
